Ceva Animal Health invests in new 7,000 m² vaccine manufacturing facility to expand global production capacity

26-Nov-2024

Ceva animal health (Ceva) unveils its latest investment in European vaccine manufacturing, with the construction of a new facility in Hungary, expanding the capacity of Ceva Phylaxia. This development will establish a 7,000 m2 plant in Monor, Hungary withthe most advanced technologies,where Ceva will produce fermentation-based multicomponent inactivated vaccines for animals.

Ceva Animal Health (Ceva)

For over 20 years, Ceva has been a strong advocate for prevention through vaccination, heavily investing in preventive medicine to significantly improve the health of husbandries but also to fight zoonotic and emerging diseases, contributing to prepare for future pandemics.

Today, 54% of Ceva’s R&D budget is dedicated to vaccine development and the company already provides more than 50 vaccines to fight 19 zoonotic diseases.

With this investment, it will further strengthen its position, producing more than 8 billion doses of vaccines in this new manufacturing plant annually, on top of other animal health products.

“Building a new facility is always a significant milestone in the life of a company. In Hungary, we already benefit from a strong historical expertise with our Ceva Phylaxia campus. With the addition of this new production unit in Monor, we aim to create new synergies to advance preventive medicine. This project reflects our commitment to supporting farmers worldwide by developing tailored solutions to tackle emerging diseases and new variants. It embodies our ambition to build a promising future for our company, employees, and partners, both in Hungary and internationally, while strengthening our research and development capabilities.” says Marc Prikazsky, Chairman and CEO of Ceva Animal Health.

The new plant is scheduled to start operations at the end of 2026.

Other news from the department manufacturing

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Rentschler Biopharma announces largest single investment at its headquarters in Germany - Construction of a new buffer media station in Laupheim

Rentschler Biopharma announces largest single investment at its headquarters in Germany - Construction of a new buffer media station in Laupheim

Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Daiichi Sankyo's investments in cancer drugs are taking shape - From Bavaria to the world: Daiichi Sankyo transfers technology for the development and production of antibody-drug conjugates to Germany

Daiichi Sankyo's investments in cancer drugs are taking shape - From Bavaria to the world: Daiichi Sankyo transfers technology for the development and production of antibody-drug conjugates to Germany

Waldner: Ground-breaking for new powder coating plant

Waldner: Ground-breaking for new powder coating plant

Roche lays the foundation for the diagnostics production of the future in Germany - Investment of more than 600 million euros in a high-tech production center - Roche's largest single investment in Germany to date

Roche lays the foundation for the diagnostics production of the future in Germany - Investment of more than 600 million euros in a high-tech production center - Roche's largest single investment in Germany to date

ProBioGen expands protein and virus manufacturing to drive continued growth

ProBioGen expands protein and virus manufacturing to drive continued growth

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Sensirion opens additional production building in Debrecen

Sensirion opens additional production building in Debrecen

Frank Winkler receives the Brain Prize 2025 - The interaction between the nervous system and cancer is increasingly coming into focus

Frank Winkler receives the Brain Prize 2025 - The interaction between the nervous system and cancer is increasingly coming into focus

CorTec Welcomes Dr. Frank Desiere as Chief Executive Officer - A Strengthened Leadership Team to Accelerate Growth and Innovation

CorTec Welcomes Dr. Frank Desiere as Chief Executive Officer - A Strengthened Leadership Team to Accelerate Growth and Innovation

New Leadership at Andreas Hettich GmbH - After 20 years of successful leadership by the Eberle family, the Hettich Group is entering a new, forward-looking phase

New Leadership at Andreas Hettich GmbH - After 20 years of successful leadership by the Eberle family, the Hettich Group is entering a new, forward-looking phase